S'abonner

Effects of short-term ambient particulate matter exposure on the risk of severe COVID-19 - 05/05/22

Doi : 10.1016/j.jinf.2022.01.037 
Zhongqi Li a, 1, Bilin Tao a, 1, Zhiliang Hu b, Yongxiang Yi b, Jianming Wang a,
a Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China 
b Nanjing Public Health Medical Center, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China 

Corresponding author at: 101 Longmian Ave., Nanjing 211166, China.101 Longmian Ave., Nanjing, , China. Telephone: 025-86868414.211166

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

Ambient particulate matter exposure has a lag effect on COVID-19.
PM10 and PM2.5 are positively related to the risk of severe COVID-19.
Curbing outdoor PM pollution will help decrease the burden of COVID-19.

Le texte complet de cet article est disponible en PDF.

Abstract

Objectives

Previous studies have suggested a relationship between outdoor air pollution and the risk of coronavirus disease 2019 (COVID-19). However, there is a lack of data related to the severity of disease, especially in China. This study aimed to explore the association between short-term exposure to outdoor particulate matter (PM) and the risk of severe COVID-19.

Methods

We recruited patients diagnosed with COVID-19 during a recent large-scale outbreak in eastern China caused by the Delta variant. We collected data on meteorological factors and ambient air pollution during the same time period and in the same region where the cases occurred and applied a generalized additive model (GAM) to analyze the effects of short-term ambient PM exposure on the risk of severe COVID-19.

Results

A total of 476 adult patients with confirmed COVID-19 were recruited, of which 42 (8.82%) had severe disease. With a unit increase in PM10, the risk of severe COVID-19 increased by 81.70% (95% confidence interval [CI]: 35.45, 143.76) at a lag of 0–7 days, 86.04% (95% CI: 38.71, 149.53) at a lag of 0–14 days, 76.26% (95% CI: 33.68, 132.42) at a lag of 0–21 days, and 72.15% (95% CI: 21.02, 144.88) at a lag of 0–28 days. The associations remained significant at lags of 0–7 days, 0–14 days, and 0–28 days in the multipollutant models. With a unit increase in PM2.5, the risk of severe COVID-19 increased by 299.08% (95% CI: 92.94, 725.46) at a lag of 0–7 days, 289.23% (95% CI: 85.62, 716.20) at a lag of 0–14 days, 234.34% (95% CI: 63.81, 582.40) at a lag of 0–21 days, and 204.04% (95% CI: 39.28, 563.71) at a lag of 0–28 days. The associations were still significant at lags of 0–7 days, 0–14 days, and 0–28 days in the multipollutant models.

Conclusions

Our results indicated that short-term exposure to outdoor PM was positively related to the risk of severe COVID-19, and that reducing air pollution may contribute to the control of COVID-19.

Le texte complet de cet article est disponible en PDF.

Keywords : Particulate matter, COVID-19, Severity, Delta variant, Time-series


Plan


© 2022  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 5

P. 684-691 - mai 2022 Retour au numéro
Article précédent Article précédent
  • Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
  • Heather J. Whitaker, Ruby S.M. Tsang, Rachel Byford, Nick J. Andrews, Julian Sherlock, Praveen Sebastian Pillai, John Williams, Elizabeth Button, Helen Campbell, Mary Sinnathamby, William Victor, Sneha Anand, Ezra Linley, Jacqueline Hewson, Silvia DArchangelo, Ashley D. Otter, Joanna Ellis, Richard F.D. Hobbs, Gary Howsam, Maria Zambon, Mary Ramsay, Kevin E. Brown, Simon de Lusignan, Gayatri Amirthalingam, Jamie Lopez Bernal
| Article suivant Article suivant
  • Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England
  • Samantha J Westrop, Heather J Whitaker, Annabel A Powell, Linda Power, Corinne Whillock, Helen Campbell, Ruth Simmons, Lenesha Warrener, Mary E Ramsay, Shamez N Ladhani, Kevin E Brown, Gayatri Amirthalingam

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.